Trials / Recruiting
RecruitingNCT06316791
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Juventas Cell Therapy Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Exploratory clinical study of CNCT19 anti CD19 cell therapy in the treatment of refractory autoimmune diseases,To evaluate the safety and tolerability of CNCT19 in patients with refractory systemic lupus erythematosus (lupus nephritis, immune thrombocytopenia), refractory ANCA-associated vasculitis, and refractory dermatomyositis on the basis of standard of care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | single dose of CNCT19 | Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously. |
Timeline
- Start date
- 2021-12-14
- Primary completion
- 2025-12-13
- Completion
- 2025-12-13
- First posted
- 2024-03-18
- Last updated
- 2025-02-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06316791. Inclusion in this directory is not an endorsement.